MAP2K3 and colorectal carcinoma: To further validate AT9283 as MKDMA drug, analyses at transcriptional levels demonstrated that AT9283 treatments modulated at similar extent the identified MKK3-dependent gene signatures with both tested CRC lines (Fig. 1E).